IQVIA reported strong Q4 2025 results with revenue up 10.3%, driven by growth in both TAS and R&D Solutions, and provided 2026 guidance for continued growth. Management extensively defended its business model against AI disruption fears, highlighting the proprietary nature of its data and domain expertise as a moat. The company also announced a simplified two-segment reporting structure for 2026 and the acquisition of Cedar Gate Technologies. Q4 2025 revenue grew 10.3% reported, and full-year 2025 revenue grew 5.9%, above guidance.
IQVIA reported strong Q4 2025 results with revenue up 10.3%, driven by growth in both TAS and R&D Solutions, and provided 2026 guidance for continued growth. Management extensively defended its business model against AI disruption fears, highlighting the proprietary nature of its data and domain expertise as a moat. The company also announced a simplified two-segment reporting structure for 2026 and the acquisition of Cedar Gate Technologies. Q4 2025 revenue grew 10.3% reported, and full-year 2025 revenue grew 5.9%, above guidance.
Management spent significant time defending the business against AI disruption fears and reiterating the positive outlook, indicating a response to external pressure.
Fourth quarter revenue growth accelerated with record backlog. Management spent significant time defending the business against AI disruption fears and reiterating the positive outlook, indicating a response to external pressure.
Management views AI as a positive, differentiating force, emphasizing proprietary data and domain expertise as key moats, and cites growing demand for AI-enabled offerings and the deployment of over 150 AI agents across workflows. They argue AI will augment rather than replace…
Management views AI as a positive, differentiating force, emphasizing proprietary data and domain expertise as key moats, and cites growing demand for AI-enabled offerings and the deployment of over 150 AI agents across workflows. They argue AI will augment rather than replace…
Management views AI as a positive, differentiating force, emphasizing proprietary data and domain expertise as key moats, and cites growing demand for AI-enabled offerings and the deployment of over 150 AI agents across workflows. They argue AI will augment rather than replace their services.
Fourth quarter revenue growth accelerated with record backlog. Management spent significant time defending the business against AI disruption fears and reiterating the positive outlook, indicating a response to external pressure.
Management spent significant time defending the business against AI disruption fears and reiterating the positive outlook, indicating a response to external pressure.
“Under this new reporting segment model, the CSMS segment, which has become more closely integrated into commercial offerings...is incorporated into the TAO segment which is renamed Commercial Solutions.”
“I should point out that in the fourth quarter, our cancellations, while in the normal range, were really slightly above the normal range due to specific idiosyncratic aspects of certain trials that had to be canceled.”
“The biggest driver of the gross margin decline you saw was very strong pass-through growth in the quarter. Okay. And there's some mixed, product-mixed impact that gets into that as well. Now, as we go into next year...the pass-through grow…”
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2026 | $12.55–$12.85 | $12.70 | GUIDED |
| Revenue | FY2026 | $17.15B–$17.35B | $17.25B | GUIDED |
| RevenueCOMMERCIAL_SOLUTIONS | FY2026 | $7.2B–$7.3B | $7.25B | GUIDED |
| RevenueRDS | FY2026 | $9.9B–$10B | $9.95B | GUIDED |
| Revenue | FY2026 Q1 | $4.15B–$4.5B | $4.325B | GUIDED |
| Дата прогноза | Показатель | Целевой период | Прогноз | Факт | Результат |
|---|---|---|---|---|---|
| FY2026 Q1 | EPS | FY2026 Q2 | $2.98–$3.08 | $3.15 | Met / beat |
| FY2026 Q1 | Revenue | FY2026 Q2 | $4.28B–$4.34B | $4.368B | Met / beat |
IQVIA is deepening its partnership with AWS, positioning AWS as its preferred cloud provider for its AI and agentic capabilities. This signals continued cloud spending by IQVIA and a strong strategic partnership between the two, likely benefiting AWS's healthcare and life sciences revenue.
“We announced the strategic collaboration with Amazon Web Services, naming AWS as our preferred agentic cloud provider to accelerate the industry's digital transformation.”
… Q4, reaching $33 billion, according to BioWorld. On the commercial side, TABS continued to perform very well in the fourth quarter, achieving better than expected results, despite the anticipated tougher year-over-year comparisons. We delivered growth in TABS of 9.8% reporting 7.1% at constant currency, highlighting the resilience of our broader commercial portfolio. And now a few highlights of business activity in the report. We announced the strategic collaboration with Amazon Web Services, naming AWS as our preferred agentic cloud provider to accelerate the industry's digital transformation. With the world's largest pharmaceutical companies already relying on Acuvia and AWS, we believe this partnership will make AI more readily available across life sciences, medical affairs, and healthcare analytics, and enable faster delivery of lifesaving treatments to patients worldwide. Acuvia was recognized by Everest Group for our AI leadership, the only clinical research organization to receive the number one ranking for generative AI leadership in life sciences. You will recall that we started on this AI journey quite a while ago, and specifically, a little more than a year ago, we …
IQVIA sees its partnership with NVIDIA as crucial to its AI strategy, indicating that AI capabilities and tools from NVIDIA are being integrated into IQVIA's core product offerings. This validates NVIDIA's broader push into healthcare and life sciences.
“You will recall that we started on this AI journey quite a while ago, and specifically, a little more than a year ago, we announced a partnership with NVIDIA, with whom we have been working for over a year to build agents into our”
… on Acuvia and AWS, we believe this partnership will make AI more readily available across life sciences, medical affairs, and healthcare analytics, and enable faster delivery of lifesaving treatments to patients worldwide. Acuvia was recognized by Everest Group for our AI leadership, the only clinical research organization to receive the number one ranking for generative AI leadership in life sciences. You will recall that we started on this AI journey quite a while ago, and specifically, a little more than a year ago, we announced a partnership with NVIDIA, with whom we have been working for over a year to build agents into our workflows, both in clinical and commercial. And we have made significant progress to date. In commercial, demand for our AI-driven innovations is gaining momentum with our clients, especially in large pharma. A few examples. The top 20 pharma clients selected IQVIA to provide comprehensive AI-enabled information and analytics solutions for a major US gastroenterology franchise. The top 15 pharma clients chose IQVIA as the strategic partner for a multiyear program to deliver analytics and agentic AI solutions across the enterprise. Another pharma client …
IQVIA noted that cancellations in Q4 were 'slightly above the normal range' due to idiosyncratic reasons, but overall demand metrics (pipeline, RFP flow, win rates) improved, and backlog reached a record high. — Despite a slightly elevated cancellation rate, the strong bookings and growth in backlog indicate a healthy overall demand environment for clinical research services, a positive signal for the whole CRO sector.
… this growth. Fourth quarter adjusted EBITDA increased 5% versus prior year. Fourth quarter adjusted diluted EPS of $3.42 increased 9.6% year-over-year. On a clinical side, net bookings totaled over $2.7 billion growing 7% year-over-year, 5% sequential. This resulted in a net book-to-deal ratio of 1.18, reflecting the continued improvement in customer trends, as well as solid execution from our sales teams. I should point out that in the fourth quarter, our cancellations, while in the normal range, were really slightly above the normal range due to specific idiosyncratic aspects of certain trials that had to be canceled. Key demand metrics for the quarter continue to be positive. A qualified pipeline is about 10% higher year over year, with growth across all customer sets. RFP flow grew double digits year over year, with growth across all segments, largest gains in large pharma and in EBP. Our win rates improved year over year, several percentage points. Backlog reached a new record of $32.7 billion at the end of the quarter, growing 5.3% compared to the prior year. And encouragingly, EVP funding was strong in Q4, reaching $33 billion, according to BioWorld. On the commercial …
IQVIA is recasting its reporting segments, moving CSMS into a new 'Commercial Solutions' segment and transferring $674M of late-phase real-world offerings into R&D Solutions. This could signal that late-phase clinical work is becoming more bundled with core development services.